# Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis

> **NCT07632846** · PHASE2 · RECRUITING · sponsor: **Horus University** · enrollment: 50 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Roflumilast 500 Mcg Oral Tablet
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT07632846
- **Lead sponsor:** Horus University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-19
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632846, "Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07632846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*